



Published in final edited form as:

*Curr Opin Genet Dev.* 2020 February ; 60: 119–126. doi:10.1016/j.gde.2020.02.017.

## DNA Polymerase theta (Pol $\theta$ ) – an error-prone polymerase necessary for genome stability

**Alessandra Brambati, Raymond Barry, Agnel Sfeir\***

Skirball Institute of Biomolecular Medicine, Department of Cell Biology, NYU School of Medicine, New York, NY 10016, USA

### Abstract

Mammalian cells have evolved multiple pathways to repair DNA double strand breaks (DSBs) and ensure genome stability. In addition to non-homologous end-joining (NHEJ) and homologous recombination (HR), cells evolved an error-prone repair pathway termed microhomology-mediated end joining (MMEJ). The mutagenic outcome of MMEJ derives from the activity of DNA polymerase theta (Pol $\theta$ ) – a multidomain enzyme that is minimally expressed in normal tissue but overexpressed in tumors. It has become evident that Pol $\theta$  expression is critical for the proliferation of HR deficient cancer cells. As a result, this mutagenic repair emerged as an attractive target for cancer therapy, and inhibitors are currently in pre-clinical development. Here we review the multifunctionality of this enigmatic polymerase, focusing on its role during DSB repair in mammalian cells and its impact on cancer genomes.

### Keywords

DNA damage; DNA Polymerase theta; Pol $\theta$  dysfunctional telomeres; DSB; MMEJ; alt-EJ

### DNA double-strand break repair in mammalian cells

DNA double-strand breaks (DSBs) are highly deleterious lesions that arise due to exogenous agents, including ionizing radiation and chemotherapeutic drugs. In addition, DSBs accumulate as a result of DNA replication, meiosis, and the assembly and diversification of antigen receptor genes by Class Switch and V(D)J recombination<sup>1</sup>. The ends of linear chromosomes may also be recognized as DSBs when telomeres are rendered dysfunctional following telomerase deficiency or upon the removal of the protective Shelterin complex<sup>2</sup>. Different sources of DSBs lead to diverse chemistry at DNA ends that can be resolved using various pathways to ensure genome stability.

\*Correspondence: Agnel Sfeir, Skirball Institute NYU Langone Medical center 540 First Avenue 4<sup>th</sup> floor/ Lab3 New York, NY 10016, Phone: (646) 501 6742, agnel.sfeir@med.nyu.edu.

Declaration of interests

Agnel Sfeir is a co-founder, consultant, and shareholder in REPARE Therapeutics.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The most studied DSB repair mechanisms include non-homologous end-joining (NHEJ) that uses little or no homology to seal DNA ends, and homologous recombination (HR) that employs the sister chromatid as template to promote error-free repair (Figure 1). NHEJ is the main DSB repair pathway in mammalian cells. This canonical end-joining pathway is initiated when the Ku70/80 (Ku) heterodimer recognizes broken DNA ends and recruits DNA-dependent protein kinase catalytic subunit (DNA-PKcs). The DNA-PK complex then phosphorylates numerous factors to promote end-joining by Ligase 4 (Lig4)<sup>3</sup>. NHEJ employs additional end-processing enzymes that are essential for the joining of chemically incompatible ends, including Artemis, polynucleotide kinase 3' phosphatase (PNKP), and two family X-Polymerase – Pol $\lambda$  and Pol $\mu$ <sup>3</sup>. Although NHEJ can act throughout the cell cycle, its activity is predominant in G1. On the other hand, the activity of HR is restricted to S and G2 phases of the cell cycle<sup>4</sup>. HR requires DNA resection, where nucleolytic degradation of a DSB generates a 3' single-stranded (ss) DNA overhang. This process is initiated by the MRE11-RAD50-NBS1 complex (MRN) in conjunction with CtIP. Extended resection is then catalyzed redundantly by EXO1 and DNA2-BLM<sup>5</sup>. Following resection, the 3' ssDNA tail is bound by RPA which is subsequently exchanged for RAD51 through the action of BRCA2 and PALB2<sup>6</sup>. RAD51 nucleofilaments mediate strand invasion and homology search on the sister chromatid. Ultimately, missing nucleotides are filled-in by copying the undamaged chromatid and repair is completed with minimal alterations to the original sequence<sup>6</sup>.

### Microhomology-mediated end joining, an intrinsically mutagenic repair pathway

In addition to the well-characterized NHEJ and HR, mammalian cells employ a mechanistically distinct, yet less-understood pathway termed Microhomology-Mediated End Joining (MMEJ). MMEJ is part of a broader and error-prone mechanism of end joining, known as alternative end joining (alt-EJ) (Figure 1). Repair by MMEJ is driven by the annealing of micro-homologous sequences flanking the DNA ends, and its outcome is mutagenic due to deletions and insertions that scar break sites. MMEJ activity has been detected in all kingdoms of life and studied in bacteria<sup>7,8</sup>, yeast<sup>9</sup>, flies<sup>10</sup>, worms<sup>11</sup>, plants<sup>12</sup>, fish<sup>13</sup> and mammals<sup>14,15</sup>. Its activity was first described in NHEJ defective *S. cerevisiae* mutants<sup>9</sup> and found to be dependent on the presence microhomology<sup>9</sup>. Early evidence for MMEJ in mammalian cells emerged from the analysis of Class Switch Recombination (CSR) in NHEJ-deficient B cells<sup>14</sup>. MMEJ was initially viewed as a back-up pathway for canonical repair. Consistent with substrates being rerouted to MMEJ when HR and NHEJ are compromised, cells lacking BRCA1/2, Ku, and Lig4 rely on MMEJ for survival<sup>16–18</sup>. However, it has become evident that in certain contexts, MMEJ operates even when NHEJ and HR are proficient. For example, MMEJ was found to be essential to repair DSBs in the developing zebrafish embryos<sup>13</sup>. Furthermore, MMEJ activity was detected during V(D)J recombination in NHEJ-proficient B cells that carry mutations in the RAG recombination genes<sup>15</sup>. Accordingly, MMEJ is no longer viewed as a back-up repair mechanism. Nevertheless, it remains unclear as to when MMEJ prevails over other repair pathways and what prevents it from accessing substrates that are typically repaired by HR and NHEJ.

Evidence for MMEJ activity at deprotected telomeres emerged from the analysis of telomerase-deficient mice, where chromosome end-to-end fusions persisted in the absence of Lig4 and DNA-PKcs<sup>19</sup>. Subsequently, sequence analysis of telomere fusions in cells derived from chronic lymphocytic leukemia (CLL) and ataxia-telangiectasia-like disorder (ATLD) patients highlighted an MMEJ signature comprising frequent microhomology, deletions, and insertions<sup>20–22</sup>. Furthermore, depletion of MMEJ factors compromised the ability of cancer cells to escape telomere crisis<sup>20</sup>, indicating that this mutagenic repair can foster genome instability in the early stage of tumorigenesis to promote cancer progression. Mechanistic insight into how mammalian telomeres suppress MMEJ was obtained through genetic experiments in mouse cells<sup>23,24</sup> which revealed that mutagenic repair is fully unleashed upon the depletion of all subunits of the Shelterin complex and in the absence of Ku. Interestingly, the function of MMEJ at telomeres is not confined to the very tip of chromosomes. DSBs internal to telomeric repeats are also repaired by MMEJ as opposed to canonical NHEJ, potentially implicating MMEJ during the repair of specialized loci such as telomere repeats<sup>25</sup>.

### Mechanistic basis of microhomology-mediated end joining

Our current understanding of the mechanistic basis of MMEJ derives primarily from genetic studies in model organisms and based on different sources of DSBs. The first step in MMEJ is shared with HR and involves MRE11/CtIP dependent resection. This exposes flanking microhomology and allows base pairing of ssDNA ends<sup>26</sup>. Evidences point to a role for PARP1 in facilitating annealing of resected ends<sup>27,28</sup>. Following synapsis, DNA polymerase theta (Pol $\theta$ ) fills-in the flanking ssDNA regions. This then stabilizes paired intermediates and prevents long-range resection that would otherwise promote HR. MMEJ is completed when Ligase 3 seals DNA ends<sup>29</sup>. Annealing can also be driven by internal microhomology which then leads to 3' ssDNA flaps that must be removed prior to fill-in synthesis and ligation. Recent work implicated the flap endonuclease, FEN1 during this processing step. Specifically, FEN1 was identified in a genome-wide CRISPR-Cas9 screen for genes that are synthetic lethal with mutant BRCA genes and found to promote MMEJ using a reporter system<sup>30</sup>.

Only a handful of MMEJ factors have been characterized so far, and efforts are currently underway to unveil the full genetic make-up of this pathway. A better understanding of factors upstream of Pol $\theta$ , including ones that shape the chromatin landscape of DSBs, will provide insight into when and how cells opt for mutagenic MMEJ over HR and NHEJ. A recent study identified HMCES (5-Hydroxymethylcytosine binding, embryonic stem cell-specific protein) as a novel MMEJ factor<sup>31</sup> that promotes efficient CSR in mature B cells. *In vitro* assays detected HMCES binding at resected DNA substrates, suggesting that it could act prior to the annealing step. However, the precise function of HMCES during MMEJ and whether it is active beyond CSR remains to be determined.

### MMEJ mutagenicity is attributed to the promiscuous activity of Pol $\theta$

A distinguishing feature of MMEJ in higher eukaryotes is the presence of nucleotide insertions at break sites. Insertions, which are highly mutagenic, have been attributed to the

activity of Pol $\theta$  that is encoded by the *POLQ* gene. Pol $\theta$  was identified in *D. melanogaster* through the analysis of mus308 mutants that displayed hypersensitivity to interstrand cross-links inducing agents<sup>32</sup>. Thereafter, Pol $\theta$  activity was linked to MMEJ during the repair of DSBs induced by P-element transposition in flies<sup>33</sup>. Since then, the role of Pol $\theta$  in MMEJ has been characterized in several multicellular organisms including worms, fish, mammals, and plants, whereas its homologs are lacking in yeast and other fungi<sup>34</sup>. In mammals, inhibition of Pol $\theta$  sensitizes cells to DSB inducing agents, including bleomycin, etoposide, camptothecin and irradiation<sup>35,36</sup>. Its function in MMEJ-mediated repair has been established based on the analysis of endonuclease-cleavage reporter constructs, CRISPR-Cas9 induced breaks in human and mouse cells<sup>16,17,36-39</sup>, and chromosomal translocation in mouse cells<sup>7</sup> (Figure 2). In all cases, Pol $\theta$  activity scarred repair junctions by means of nucleotide insertions at break sites. Notably, Pol $\theta$ -driven MMEJ activity was also found to be critical during the random integration of foreign DNA into host genomes in plants and mammals<sup>12,37,40</sup>. Work from our laboratory established the role of Pol $\theta$  during the processing of dysfunctional telomeres<sup>17</sup>. Sequence analysis of telomere fusions in cells lacking NHEJ revealed breakpoints with non-telomeric nucleotide insertions that were diminished upon Pol $\theta$  inhibition<sup>17</sup>. Taken together, these studies underscore templated insertions by Pol $\theta$  as an evolutionary conserved feature of MMEJ. This raises the question of why would cells retain a mutagenic repair mechanism when more accurate pathways such as HR and NHEJ are in place. Emerging evidence from *C. elegans* suggests that repair by MMEJ could promote genome diversification. Specifically, insertions and small deletions indicative of Pol $\theta$  activity in lab strains are also evident in the genomes of wild isolates<sup>41</sup>. It would be interesting to investigate whether Pol $\theta$  is a source of genome diversity in higher eukaryotes including human germ cells.

## DNA polymerase Pol $\theta$ as a multifunctional enzyme

Pol $\theta$  is a unique enzyme, as it is the only DNA polymerase that contains a helicase-like domain at its N-terminus (Figure 3), and the modalities are separated by a large unstructured central domain. Structural analysis of the different enzymatic domains confirmed that they form dimers and possibly multimers in solution. It has been proposed that dimerization helps Pol $\theta$  tether DNA ends together and stabilize synapsed intermediates. Whether Pol $\theta$  dimerization occurs *in vivo* is yet to be established<sup>42-44</sup>.

Pol $\theta$ -polymerase domain belongs to the A-family DNA polymerases but lacks proofreading activity<sup>45</sup>. Pol $\theta$ -polymerase activity has been investigated biochemically using a range of DSB substrates and tested genetically in several model systems. *In vitro* characterizations of human Pol $\theta$ -polymerase identified template-dependent as well as template-independent DNA synthesis<sup>46,47</sup>. Templated nucleotides are copied from regions flanking the break sites *in trans* and *in cis*. The latter employs a unique “snap-back” reaction that self-copies the ssDNA end<sup>47</sup>. On the other hand, non-templated insertions have been mainly characterized *in vitro* using full-length protein as well as the polymerase domain and are attributed to a terminal transferase activity that is stimulated by Mn<sup>++</sup><sup>48</sup>. However, template-independent activity is abolished in the presence of Mg<sup>++</sup> and when ssDNA substrates that cannot self-anneal were used<sup>49</sup>. Of note, Pol $\theta$ -dependent nucleotide insertions not matching flanking DNA sequences were detected at chromosomal translocations as well as telomere fusions in

mouse cells<sup>47</sup>. These nucleotides could either be inserted by a template-independent activity or through iterative cycles of templated copying, slippage, and re-priming. The identification of a separation of function mutant would be critical to ascertain the relevance of a terminal transferase Pol $\theta$  activity *in vivo*.

Pol $\theta$ -helicase belongs to the SF2 family of helicases that includes Hel308 and RecQ<sup>50</sup>. Inhibition of Pol $\theta$ -helicase manifested in reduced microhomology at repair junctions in flies<sup>10</sup> and impaired chromosomal translocation in mouse cells<sup>51</sup>. *In vitro* assays uncovered a strong ATPase activity that is stimulated by ssDNA<sup>43,50</sup>. Recent work from our laboratory revealed that Pol $\theta$ -helicase exhibits an ATP-dependent DNA annealing activity that facilitate base-pairing of ssDNA, even when pre-bound by RPA. In effect, we showed that Pol $\theta$  employs its ATPase activity to counteract RPA binding and promote the annealing of resected DNA substrates. This would ultimately favor repair by MMEJ while preventing HR<sup>51</sup>. Consistent with a role for Pol $\theta$ -helicase in suppressing HR, Ceccaldi and colleagues found that inhibition of Pol $\theta$ -helicase increases RAD51 loading and HR-mediated repair of I-SceI-based reporters<sup>16</sup>. Furthermore, inhibition of Pol $\theta$ -helicase in mouse cells enhanced the efficiency of HR-mediated CRISPR-Cas9 gene targeting<sup>51</sup>.

## The function of Pol $\theta$ in other repair pathways

In addition to its critical role during MMEJ, Pol $\theta$  has overlapping functions with other repair pathways, including translesion synthesis, base-excision repair (BER), and replication repair (Figure 2). Pol $\theta$  catalyzes DNA synthesis across abasic sites and possesses a mild 5'-dRP lyase activity<sup>45,50,52</sup>, both relevant for BER. Genetic data suggest that Pol $\theta$  could serve as a back-up for Pol $\beta$  during BER. Specifically, DT40 cells lacking both Pol $\theta$  and Pol $\beta$  are sensitive to MMS due to reduced BER activity<sup>53</sup>. Furthermore, a CRISPR-Cas9 genome-wide screen in *Polq* deficient mouse cells identified multiple genes involved in the BER pathway as synthetic lethal interactors with Pol $\theta$ <sup>54</sup>. Biochemical studies have determined that Pol $\theta$  is unable to bypass pyrimidine dimers, a type of UV photoproduct. However, the polymerase domain is capable of extending mismatched DNA termini and could therefore indirectly contribute to repairing UV-induced lesions. In support of this hypothesis, *Polq*<sup>-/-</sup> mice have an increased risk of developing UV-induced skin cancers, and the incidence raises dramatically when combined with *Polh* deficiency<sup>55</sup>.

MMEJ activity is maximal in S phase and it is therefore not surprising that Pol $\theta$  has been implicated in the repair of replication forks. The first evidence for Pol $\theta$  function in replication repair came upon examining G4 DNA stability in *C. elegans*. Worms lacking FANCD1, which ensures replication across G4 sites, rely on Pol $\theta$  to repair collapsed forks and prevent the accumulation of large deletions<sup>11</sup>. Furthermore, Pol $\theta$  depletion in human cells reduces replication speed and compromises replication fork restart in the presence of hydroxyurea<sup>16</sup>. Direct evidence for Pol $\theta$  role at collapsed forks is based on a recent study using *Xenopus* egg extracts. Specifically, supplementing frog extracts with mitotic kinases to trigger replisome disassembly led to fork breakage and Pol $\theta$  dependent rearrangement<sup>56</sup>. The observation that Pol $\theta$  mediated repair is not inhibited by mitotic kinases raises the interesting possibility that MMEJ is the predominant DSB repair pathway in mitosis when NHEJ and HR are known to be greatly repressed<sup>4</sup>.

## Polθ inhibition during cancer therapy

Expression of Polθ is tightly regulated; the polymerase is largely repressed in somatic cells and upregulated in several human cancers, including lung, gastric, and colorectal<sup>57</sup>. In addition, Polθ levels are especially high in HR deficient breast<sup>58</sup> and ovarian cancers<sup>16</sup> and associated with poor clinical outcomes. The underlying mechanism that regulates Polθ expression remains unknown. Nevertheless, its expression pattern and the reliance of BRCA mutated cells on MMEJ for survival<sup>16,17</sup> renders this unique polymerase an appealing target for cancer treatment<sup>59</sup>. In fact, efforts are currently underway to develop Polθ inhibitors for the treatment of HR defective tumors.

Exploiting synthetic lethality in DNA repair to eliminate cancer cells is best exemplified by the PARP1-BRCA genetic interaction. The profound impact of PARP1 inhibition on the survival of a sizeable fraction HR defective tumors led to the development of five PARP inhibitors that are currently in clinical trials. Despite the clinical benefits achieved in several *BRCA*-mutated cancers, resistance to therapy is a common theme among all PARP inhibitors. Resistance mechanisms are not fully understood, but evidence suggests that at least a subset of these tumors involve mutations in NHEJ factors that would respond to Polθ inhibition<sup>60,61</sup>.

While Polθ synthetic lethality manifests in the context of HR and NHEJ defective tumors, rearrangements consistent with MMEJ activity have been detected in wide range of cancers<sup>62</sup>. Furthermore, MMEJ footprint is found at telomere fusions in CLL<sup>21</sup>, translocations that drive lymphomas<sup>63</sup>, and during chromothripsis<sup>64</sup>. Mutagenic repair by Polθ could drive genome plasticity that fuels cancer progression and therefore, its inhibition could limit the mutational rate that renders tumors resistant to cytotoxic therapies. In conclusion, targeting Polθ has substantial clinical potential and this can only be realized upon a complete understanding of the mechanistic basis of MMEJ.

## Acknowledgements

We thank Michael Smith and Marco Tigano for providing feedbacks on this manuscript. Work on Polθ in the Sfeir lab is supported by a grant from NIH/NCI (R01CA229161) and a fellowship from the Pershing Square Sohn Cancer Research Alliance.

## Biography

**Schimmel *et al.*, 2017.** This study reveals that in mouse embryonic stem cells Polθ acts in parallel and redundantly with NHEJ to repair DSBs and that virtually all DSBs are repaired through these two pathways. The author induced a blunt DSB with CRISPR-Cas9 in a reporter gene and analyzed the repair products revealing the mutation spectra of Polθ and NHEJ factors. The study supports the notion that Polθ repair relies on microhomology. Surprisingly, in the case of long 3' or 5' ssDNA overhangs, NHEJ dominates over MMEJ.

**Deng *et al.*, 2019.** This is the first study that provides evidence of Polθ-mediated MMEJ events during mitosis. The authors showed that in *X. laevis* extracts the replisome disassembly during mitosis causes replication fork breakage that form rearrangements driven Polθ and characterized by microhomology.

**Balagere et al., 2019.** This study shows that HMCES, a protein reported to protect stalled replication forks, plays an additional role in the MMEJ pathway during class switch recombination in murine B cells. The author demonstrates the ability of HMCES to interact with DNA overhangs of different lengths.

**Black et al., 2019.** The authors used a biochemical approach to characterize MMEJ at the molecular level using full-length human Pol $\theta$ . This study shows that Pol $\theta$ -helicase domain is essential for MMEJ. In addition, its central domain was proposed to regulate of Pol $\theta$  multimerization and DNA substrates requirements during MMEJ.

**Feng et al., 2019.** This study expands the synthetic lethality interactions of Pol $\theta$ . Through a CRISPR-Cas9 screen in mouse cells, the authors identified 140 genes that are required for the survival of Pol $\theta$  deficient cells. These genes belong to several pathways, including DNA repair, DNA damage signaling, and chromatin structure. Breast cancers with alterations in many of these genes had increased Pol $\theta$  and had an MMEJ genomic footprint.

## References


1. Jackson SP & Bartek J The DNA-damage response in human biology and disease. *Nature* 461, 1071–1078 (2009). [PubMed: 19847258]
2. de Lange T Shelterin-Mediated Telomere Protection. *Annu. Rev. Genet.* 52, 223–247 (2018). [PubMed: 30208292]
3. Pannunzio NR, Watanabe G & Lieber MR Nonhomologous DNA End Joining for Repair of DNA Double-Strand Breaks. *J. Biol. Chem.* jbc.TM117.000374 (2017). doi:10.1074/jbc.TM117.000374
4. Orthwein A et al. A mechanism for the suppression of homologous recombination in G1 cells. *Nature* 528, 422–426 (2015). [PubMed: 26649820]
5. Symington LS & Gautier J Double-Strand Break End Resection and Repair Pathway Choice. *Annu. Rev. Genet.* 45, 247–271 (2011). [PubMed: 21910633]
6. Wright WD, Shah SS & Heyer W-D Homologous recombination and the repair of DNA Double-Strand Breaks. *J. Biol. Chem.* jbc.TM118.000372 (2018). doi:10.1074/jbc.TM118.000372
7. Aniakwu J, Glickman MS & Shuman S The pathways and outcomes of mycobacterial NHEJ depend on the structure of the broken DNA ends. *Genes Dev.* 22, 512–527 (2008). [PubMed: 18281464]
8. Chayot R, Montagne B, Mazel D & Ricchetti M An end-joining repair mechanism in *Escherichia coli*. *Proc. Natl. Acad. Sci. U. S. A.* 107, 2141–2146 (2010). [PubMed: 20133858]
9. Boulton SJ & Jackson SP *Saccharomyces cerevisiae* Ku70 potentiates illegitimate DNA double-strand break repair and serves as a barrier to error-prone DNA repair pathways. *EMBO J.* 15, 5093–5103 (1996). [PubMed: 8890183]
10. Chan SH, Yu AM & McVey M Dual roles for DNA polymerase theta in alternative end-joining repair of double-strand breaks in *Drosophila*. *PLoS Genet.* 6, 1–16 (2010).
11. Koole W et al. A polymerase theta-dependent repair pathway suppresses extensive genomic instability at endogenous G4 DNA sites. *Nat. Commun.* 5, 1–10 (2014).
12. Van Kregten M et al. T-DNA integration in plants results from polymerase- $\theta$ -mediated DNA repair. *Nat. Plants* 2, (2016).
13. Thyme SB & Schier AF Polq-Mediated End Joining Is Essential for Surviving DNA Double-Strand Breaks during Early Zebrafish Development. *Cell Rep.* 15, 707–714 (2016). [PubMed: 27149851]
14. Yan CT et al. IgH class switching and translocations use a robust non-classical end-joining pathway. *Nature* 449, 478–482 (2007). [PubMed: 17713479]
15. Corneo B et al. Rag mutations reveal robust alternative end joining. *Nature* 449, 483–486 (2007). [PubMed: 17898768]

16. Ceccaldi R et al. Homologous-recombination-deficient tumours are dependent on Pol $\theta$  - mediated repair. *Nature* 518, 258–262 (2015). [PubMed: 25642963]
17. Mateos-Gomez PA et al. Mammalian polymerase  $\theta$  promotes alternative NHEJ and suppresses recombination. *Nature* 518, 254–257 (2015). [PubMed: 25642960]
18. Wyatt DW et al. Essential Roles for Polymerase  $\theta$ -Mediated End Joining in the Repair of Chromosome Breaks. *Mol. Cell* 63, 662–673 (2016). [PubMed: 27453047]
19. Maser RS et al. DNA-Dependent Protein Kinase Catalytic Subunit Is Not Required for Dysfunctional Telomere Fusion and Checkpoint Response in the Telomerase-Deficient Mouse. *Mol. Cell. Biol.* 27, 2253–2265 (2007). [PubMed: 17145779]
20. Jones RE et al. Escape from telomere-driven crisis is DNA ligase III dependent. *Cell Rep.* 8, 1063–1076 (2014). [PubMed: 25127141]
21. Lin TT et al. Telomere dysfunction and fusion during the progression of a human malignancy. *Blood* 44, 1899–1908 (2010).
22. Tankimanova M et al. Mre11 modulates the fidelity of fusion between short telomeres in human cells. *Nucleic Acids Res.* 40, 2518–2526 (2012). [PubMed: 22139912]
23. Rai R et al. The function of classical and alternative non-homologous end-joining pathways in the fusion of dysfunctional telomeres. *EMBO J.* 29, 2598–2610 (2010). [PubMed: 20588252]
24. Sfeir A & De Lange T Removal of shelterin reveals the telomere end-protection problem. *Science* (80-. ). 336, 593–597 (2012).
25. Doksani Y & de Lange T Telomere-Internal Double-Strand Breaks Are Repaired by Homologous Recombination and PARP1/Lig3-Dependent End-Joining. *Cell Rep.* 17, 1646–1656 (2016). [PubMed: 27806302]
26. Truong LN et al. Microhomology-mediated End Joining and Homologous Recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells. *Proc. Natl. Acad. Sci. U. S. A.* 110, 7720–7725 (2013). [PubMed: 23610439]
27. Audebert M, Salles B & Calsou P Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. *J. Biol. Chem.* 279, 55117–55126 (2004). [PubMed: 15498778]
28. Wang M et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. *Nucleic Acids Res.* 34, 6170–6182 (2006). [PubMed: 17088286]
29. Liang L et al. Human DNA ligases I and III, but not ligase IV, are required for microhomology-mediated end joining of DNA double-strand breaks. *Nucleic Acids Res.* 36, 3297–3310 (2008). [PubMed: 18440984]
30. Mengwasser KE et al. Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets. *Mol. Cell* 73, 885–899.e6 (2019). [PubMed: 30686591]
31. Balagere S et al. Article HMCES Functions in the Alternative End-Joining Pathway of the DNA DSB Repair during Class Switch Recombination in B Cells Article HMCES Functions in the Alternative End-Joining Pathway of the DNA DSB Repair during Class Switch Recombination in B C. *Mol. Cell* 1–11 (2020). doi:10.1016/j.molcel.2019.10.031
32. Harris PV et al. Molecular Cloning of *Drosophila* mus308, a Gene Involved in DNA Cross-Link Repair with Homology to Prokaryotic DNA Polymerase I Genes †. *MOLECULAR AND CELLULAR BIOLOGY* 16, (1996).
33. Chan SH, Yu AM & McVey M Dual roles for DNA polymerase theta in alternative end-joining repair of double-strand breaks in *Drosophila*. *PLoS Genet.* 6, 1–16 (2010).
34. Sfeir A & Symington LS Microhomology-Mediated End Joining : A Back-up Survival Mechanism or Dedicated Pathway ? *Trends Biochem. Sci.* 40, 701–714 (2015). [PubMed: 26439531]
35. Goff JP et al. Lack of DNA Polymerase Q Radiosensitizes bone marrow stromal cells in vitro and increases reticulocyte micronuclei after total-body irradiation. *Radiat. Res.* 172, 165–174 (2009). [PubMed: 19630521]
36. Yousefzadeh MJ et al. Mechanism of Suppression of Chromosomal Instability by DNA Polymerase POLQ. *PLoS Genet.* 10, (2014).
37. Saito S, Maeda R & Adachi N Dual loss of human POLQ and LIG4 abolishes random integration. *Nat. Commun.* 8, (2017).




38. Schimmel J et al. Mutational signatures of non-homologous and polymerase theta-mediated end-joining in embryonic stem cells. *EMBO J.* 36, e201796948 (2017).
39. Wang Z et al. DNA polymerase (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse. *J. Biol. Chem.* 294, 3909–3919 (2019). [PubMed: 30655289]
40. Zelensky AN, Schimmel J, Kool H, Kanaar R & Tijsterman M Inactivation of Pol  $\theta$  and C-NHEJ eliminates off-target integration of exogenous DNA. *Nat. Commun.* 8, 1–7 (2017). [PubMed: 28232747]
41. Van Schendel R, Roerink SF, Portegijs V, Van Den Heuvel S & Tijsterman M Polymerase  $\theta$  is a key driver of genome evolution and of CRISPR/Cas9-mediated mutagenesis. *Nat. Commun* 6, 1–8 (2015).
42. Zahn KE et al. Human DNA polymerase  $\theta$  grasps the primer terminus to mediate DNA repair. *Nat. Struct. Mol. Biol.* 22, 304–311 (2015). [PubMed: 25775267]
43. Newman JA, Cooper CDO, Aitkenhead H & Gileadi O Structure of the Helicase Domain of DNA Polymerase Theta Reveals a Possible Role in the Microhomology-Mediated End-Joining Pathway. *Structure* 23, 2319–2330 (2015). [PubMed: 26636256]
44. Black SJ et al. Molecular basis of microhomology-mediated end-joining by purified full-length Pol $\theta$ . *Nat. Commun.* 10, (2019).
45. Seki M et al. High-efficiency bypass of DNA damage by human DNA polymerase Q. *EMBO J.* 23, 4484–4494 (2004). [PubMed: 15496986]
46. Hogg M, Sauer-Eriksson AE & Johansson E Promiscuous DNA synthesis by human DNA polymerase  $\theta$ . *Nucleic Acids Res.* 40, 2611–2622 (2012). [PubMed: 22135286]
47. Walter J, Kent T, Mateos-Gomez PA, Sfeir A & Pomerantz RT Polymerase is a robust terminal transferase that oscillates between three different mechanisms during end-joining. *Elife* 5, 1–25 (2016).
48. Walter J, Kent T, Mateos-Gomez PA, Sfeir A & Pomerantz RT Polymerase is a robust terminal transferase that oscillates between three different mechanisms during end-joining. (2016). doi:10.7554/eLife.13740.001
49. He P & Yang W Template and primer requirements for DNA Pol  $\theta$ -mediated end joining. *Proc. Natl. Acad. Sci. U. S. A.* 115, 7747–7752 (2018). [PubMed: 29987024]
50. Seki M, Marini F & Wood RD POLQ (Pol  $\theta$ ), a DNA polymerase and DNA-dependent ATPase in human cells. *Nucleic Acids Res.* 31, 6117–6126 (2003). [PubMed: 14576298]
51. Mateos-Gomez PA et al. The helicase domain of Pol $\theta$  counteracts RPA to promote alt-NHEJ. *Nat. Struct. Mol. Biol.* (2017). doi:10.1038/nsmb.3494
52. Yoon JH, Choudhury JR, Park J, Prakash S & Prakash L A role for DNA polymerase  $\theta$  in promoting replication through oxidative DNA lesion, thymine glycol, in human cells. *J. Biol. Chem.* 289, 13177–13185 (2014). [PubMed: 24648516]
53. Yoshimura M et al. Vertebrate POLQ and POL $\beta$  Cooperate in Base Excision Repair of Oxidative DNA Damage. *Mol. Cell* 24, 115–125 (2006). [PubMed: 17018297]
54. Feng W et al. Genetic determinants of cellular addiction to DNA polymerase theta. *Nat. Commun.* 10, (2019).
55. Yoon JH et al. Error-Prone Replication through UV Lesions by DNA Polymerase  $\theta$  Protects against Skin Cancers. *Cell* 176, 1295–1309.e15 (2019). [PubMed: 30773314]
56. Deng L et al. Mitotic CDK promotes replisome disassembly, fork breakage, and complex DNA rearrangements. *Mol. Cell* 73, 428433 (2018).
57. Kawamura K et al. DNA polymerase  $\theta$  is preferentially expressed in lymphoid tissues and upregulated in human cancers. *Int. J. Cancer* 109, 9–16 (2004). [PubMed: 14735462]
58. Lemee F et al. DNA polymerase up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. *Proc. Natl. Acad. Sci.* 107, 13390–13395 (2010). [PubMed: 20624954]
59. Higgins BGS & Boulton SJ Beyond PARP—POL Q as an anticancer target. *Science* (80-. ). 359, 1217–1219 (2018).
60. Gupta R et al. DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity. *Cell* 173, 1–17 (2018). [PubMed: 29570990]

61. Noordermeer SM et al. The shieldin complex mediates 53BP1-dependent DNA repair. *Nature* 560, 117–121 (2018). [PubMed: 30022168]
62. Stephens PJ et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. *Nature* 462, 1005–1010 (2009). [PubMed: 20033038]
63. Zhu C et al. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. *Cell* 109, 811–821 (2002). [PubMed: 12110179]
64. Kloosterman WP et al. Constitutional Chromothripsis Rearrangements Involve Clustered Double-Stranded DNA Breaks and Nonhomologous Repair Mechanisms. *Cell Rep.* 1, 648–655 (2012). [PubMed: 22813740]




**Figure 1. Major DSB repair pathways in mammalian cells.**

DSBs in G1 are primarily repaired by NHEJ. The Ku heterodimer recognizes broken DNA and recruits DNA-PKcs to orchestrate end-joining by Lig4. During NHEJ, minimal processing of DNA ends leads to repair with minimal alteration to the original sequence. DSBs in S/G2 phases of the cell cycle are subjected to end-resection by MRN/CtIP, leading to short ssDNA that is rapidly coated by RPA. Resected DSBs are substrates for MMEJ and HR, and the choice between these pathways is poorly understood. Pol $\theta$ -helicase displaces RPA to promote the synapsis of the opposing ends. If annealing occurs using internal microhomology, flaps are generated and are processed by FEN1. Pol $\theta$  fills-in the gapped DNA and hands over the substrate to Lig3 to seal the end. When resected DNA is subject to long end-resection by EXO1/DNA2 and BLM, RPA1 is exchanged for Rad51 to promote strand invasion and copying from the sister chromatid.



**Figure 2. Overview of all reported Polθ activities.**

Representation of the various activities that are carried out by Polθ. The major and well-established Polθ function is during DSB repair by MMEJ and has been studied using different substrates and in various model systems (green). Polθ has also been linked to the repair of breaks associated with replication forks (yellow). Lastly, Polθ employs its translesion synthesis activity to bypass UV-damaged bases and abasic sites (orange).



**Figure 3. Polθ is a unique multidomain enzyme.**

Schematic representation of the different domains of human Polθ, depicting the structure and function of its helicase domain (pink), the unstructured central domain (grey) and the family-A polymerase domain (orange). The helicase domain drives MMEJ activity during chromosomal translocations, promotes Polθ dimerization, and suppresses HR and snap-back replication. The central domain contains three predicted RAD51 binding motifs that are not conserved in mouse. These motifs are implicated in suppression of HR through the inhibition of RAD51 nucleofilament formation. The primary and unequivocal function of the polymerase domain is to perform fill-in synthesis during MMEJ. The polymerase domain has also been reported to participate in tethering DNA ends. The polymerase domain comprised three insertion loops that are essential for Polθ to bypass bulky lesions and abasic sites, and were proposed to promote dimerization.